Pharmacoepidemiologic study of policosanol

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 8, 1999, Pages 458-467

  Más, Rosa ^a   Rivas, Pedro ^b   Izquierdo, José E ^b   Hernández, Reynaldo ^b   Fernández, Lilia ^a   Fernández, Julio ^a   Orta, Santa D ^c   Illnait, Jose ^a   Ricardo, Yamilet ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b Med Serv of the Min of Int Aff   (Cuba)

^c Cuban State Center for Drug Control   (Cuba)

Author keywords

Cohort study; Pharmacoepidemiology; Pharmacologic surveillance; Policosanol

Indexed keywords

ANTITHROMBOCYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT; POLICOSANOL;

ADULT; ARTICLE; BULIMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PHASE 4 CLINICAL TRIAL; POLYURIA; PRIORITY JOURNAL; STROKE; VASCULAR DISEASE; VERTIGO; WASTING SYNDROME; WEIGHT REDUCTION;

EID: 0032788819     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(99)80024-1     Document Type: Article

References (35)

1. Ferner RB. Newly licensed drugs. Br Med J. 1996;313:1157-1158.
2. Edwards R. Competing in drug safety. Lancet. 1992;342:631-632.
3. Porta MS, Hartzema AG. The contribution of epidemiology to the study of drugs. Drug Intell Clin Pharm. 1987;21:741-747.
4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-364.
5. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA. 1984;251:365-374.
6. Frick MH, Elo O, Happa K, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 S). Lancet. 1994;344:1383-1389.
8. Sheperd J, Cobe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
9. Menéndez R, Fernández I, del Río A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing cultured human fibroblasts. Biol Res. 1994;27:199-203.
10. Menéndez R, Arruzazabala ML, Más R, et al. Cholesterol-lowering effects of policosanol on rabbits with hypercholesterolemia induced by a starch-casein diet. Br J Nutr. 1997;77:923-932.
11. Pons P, Rodríguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res. 1994;14:27-33.
12. Pons P, Rodriguez M, Más R, et al. One year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res. 1994;55:1084-1092.
13. Aneiros E, Más R, Calderón B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res. 1995;56:176-182.
14. Canetti M, Moreira M, Illnait J, et al. A two year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia. Int J Clin Pharmacol Res. 1995;15:159-165.
15. Castaño G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12-month study. Curr Ther Res. 1995;56:819-828.
16. Zardoya R, Tula L, Castaño G, et al. Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function. Curr Ther Res. 1996;57:568-577.
17. Ortensi G, Gtadstein J, Valli H, Tesone PA. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res. 1997;58:390-401.
18. Canetti MM, Moreira M, Más R, et al. Effects of policosanol on primary hypercholesterolemia: A 3-year open-extension follow-up. Curr Ther Res. 1997;58:868-875.
19. Benítez M, Romero C, Más R, et al. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res. 1997;58:859-867.
20. Castaño G, Más R, Fernándex JC, et al. Open-label study of the efficacy, safety, and tolerability of policosanol in patients with high global coronary risk. Curr Ther Res. 1998;59:737-745.
21. Más R, Castaño G, Fernández JC, et al. Effect of policosanol in patients with type II hypercholesterolemia plus two or moro additional coronary risk factors. Clin Pharmacol Ther. 1999;65:439-447.
22. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393-397.
23. Crespo N, Alvarez R, Más R, et al. Effects of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: A pilot study. Curr Ther Res. 1997;58:44-51.
24. Arruzazabala ML, Carbajal D, Más R, et al. Effects of policosanol on platelet aggregation in rats. Thromb Res. 1992;69:321-327.
25. Arruzazabala ML, Valdés S, Más R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res. 1996;34:181-185.
26. Valdés S, Arruzazabala ML, Carbajal D, et al. Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res. 1996;16:67-72.
27. Scazziota A, Pons S, Altman R. Efecto del policosanol sobre la functión de las plaquetas en voluntarios sanos. Rev Iberoamer Tromb Hemos. 1996;9:58-62.
28. Carbajal D, Arruzazabala ML, Valdés S, Más R. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids. 1998;58:61-64.
29. Arruzazabala ML, Valdés S, Más R, et al. Comparative study of policosanol, aspirin and the combination of policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res. 1997;36:293-297.
30. Alemán CL, Rodeiro I, Noa M, et al. Acute, subchronic and chronic toxicity of policosanol in rats. In: Abstracts of the Sixth International Congress of Toxicology; June 28-July 3, 1992; Rome, Italy. Abstract 248.
31. Alemán C, Más R, Hernández C, et al. A 12 month study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett. 1994;70:77-87.
32. Rodriguez MD, Garcín H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutag. 1994;14:107-113.
33. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in Beagle dogs: One year study. Toxicol Lett. 1994;73:81-90.
34. Alemán CL, Más R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study. Teratog Carcinog Mutag. 1994;14:239-249.
35. Fernández L, Más R, Illnait J, Fernández JC, Policosanol: Results of a postmarketing surveillance study on 27,879 patients. Curr Ther Res. 1998;59:717-722.